26 July 2018
Visiongain’s new 138-page report Global Influenza Vaccines Market Outlook 2018-2028: Forecasts for Trivalent Influenza Vaccines (TIV) & Quadrivalent Influenza Vaccines (QIV), Revenue Forecasts and Analysis of Pipeline Developments For Fluzone / VaxiGrip, Seqirus, Fluarix / FluLaval, FluMist / Fluenz, FluBlok and Other indicates that the influenza vaccines market will generate revenues of $3.53bn in 2018.
The study analyses events, prospects and sales opportunities shaping the development, production and marketing of influenza vaccines. That investigation shows multilevel revenue forecasting and qualitative assessments. The work also explores activities of companies providing these vaccines, assessing their potentials from 2018 onwards. This vaccines market holds many commercial opportunities from 2018, including rising sales in developed and emerging countries.
Visiongain predicts that the influenza vaccines market will continue to grow at a steady pace through2018-2028. This growth is mainly driven by the ageing population globally and the increasing prevalence of chronic illness. Adding to this will be the growing demand from emerging markets as their economies prosper, their healthcare expenditures also rise.
The study shows how the market share for the various countries change due to political and economic structural changes, and also the emergence of new industry players. Further, the shifts in market share of the submarkets are also shown, shedding light on the future developments in the influenza vaccine technology. The study also includes the next major breakthrough that will transform the industry; the much awaited Universal Flu vaccine, which will provide immunity against all types of influenza viruses. A company that is currently developing this vaccine has also been interviewed in the report.
The pharmaceutical industry analyst at visiongain for this report said: “Prevalence of influenza rises globally. The most effective way to combat that widespread infection is through vaccination. As the world moves towards an ageing population, people’s susceptibility to influenza increases, raising demand for flu vaccines. Also improving healthcare systems, growing flu awareness and high birth rates in developing countries will fuel demand for existing and new influenza vaccines from 2018. The influenza vaccination industry thus holds great potential for progress and high sales. Vaccination is a stressful event, especially for children, and the company that can provide a uniquely non-stress vaccination will reap high rewards.
The influenza virus changes each year and new vaccines are required to maintain immunization against the infection. With this in mind, the influenza vaccine market can be assured of high demand. And the development of a universal influenza vaccine that provides protection against seasonal and pandemic strains of the virus could potentially transform the industry.”
Global Influenza Vaccines Market Outlook 2018-2028: Forecasts for Trivalent Influenza Vaccines (TIV) & Quadrivalent Influenza Vaccines (QIV), Revenue Forecasts and Analysis of Pipeline Developments For Fluzone / VaxiGrip, Seqirus, Fluarix / FluLaval, FluMist / Fluenz, FluBlok and Other adds to visiongain’s reports on industries and markets in healthcare. That portfolio covers pharmaceuticals, medical devices, diagnostics and outsourced services, including contract research (CROs), manufacturing (CMOs) and selling (CSOs).
Notes for Editors
If you are interested in a more detailed overview of this yearbook, please send an e-mail to email@example.com or call on +44 (0) 207 336 6100
Visiongain is one of the fastest-growing and most innovative independent media companies in Europe. Based in London, UK, visiongain produces a host of business-to-business conferences, newsletters, management reports and e-zines focusing on the energy, telecoms, pharmaceutical, defence and materials sectors.
Visiongain publishes reports produced by its in-house analysts, who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high-quality, original material to rely and depend on.
In recent years, one area of biopharmaceutical manufacturing that has come under increasing interest is ADC manufacturing.
16 January 2020
In recent years, with the advent of technology, medical practitioners and manufacturers have made huge strides in the wound care market. As one of today’s leading market research and report firms, Visiongain is committed to providing you the most up-to-date information about this exciting industry. That’s why below we’ve collected some of today’s latest products and technologies for your perusal. …
14 January 2020
With the emergence of new health technology and advances in vaccines, manufacturers and key stakeholders can position themselves to generate big returns in the coming years. However, getting ahead of the competition will require having the right tools at your disposal, which is why Visiongain is proud to offer extensive vaccine market forecasts, as well as reports from other verticals …
14 January 2020
New trials from around the world are affecting the global dermatology market on an almost daily basis, providing patients with new drugs and medical practitioners with more innovative treatment technology than ever before. That’s why Visiongain has made it their business to help inform key stakeholders and business owners about the most current changes and emerging trends. Here are a …